Ionis drug eplontersen misses primary endpoint in heart trial

July 9, 2026 2:00 AM

Ionis Pharmaceuticals (Nasdaq: IONS) and AstraZeneca announced that the CARDIO-TTRansform Phase 3 trial of eplontersen in patients with transthyretin-mediated amyloid ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found